Actively Recruiting
Repeat Breast Conserving Surgery Followed by Daily Partial Breast Irradiation in Ipsilateral Breast
Led by Case Comprehensive Cancer Center · Updated on 2026-05-07
55
Participants Needed
2
Research Sites
297 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The standard treatment for participants whose cancer has returned after breast conserving surgery is radiation given twice daily (separated by at least 6 hours) for a total of 30 treatments. The purpose of this study is to find out if giving radiation once a day for 15 treatments after repeat breast conserving surgery works as well as giving it the standard way.
CONDITIONS
Official Title
Repeat Breast Conserving Surgery Followed by Daily Partial Breast Irradiation in Ipsilateral Breast
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Recurrence must be confirmed as ductal carcinoma in-situ, invasive ductal, medullary, papillary, colloid (mucinous), tubular, or mixed histologies
- At least 3 years must have passed since last whole breast radiation
- Lesion size less than 3 cm treated with partial mastectomy
- Negative resection margins with no tumor on ink or negative re-excision
- Invasive cancer participants must have negative restaging by CT chest/abdomen and bone scan or PET
- Hormonal therapy allowed; chemotherapy allowed before or after radiation with 2-week gap; HER2 therapy can be given with radiation
- Participants must be 18 years or older
- Ability and willingness to sign informed consent
- ECOG performance status 2 or less
- Life expectancy of at least 12 months
- Open to all genders based on self-representation of gender identity
You will not qualify if you...
- Nodal or distant metastatic disease less than 3 years since prior radiation
- Invasive pure lobular carcinoma, extensive lobular carcinoma in-situ, extensive ductal carcinoma in-situ greater than 3 cm, or uncontrolled nonepithelial breast cancers
- Multicentric carcinoma or suspicious lymph nodes unless confirmed negative
- Paget's disease of the nipple
- Skin involvement
- Scleroderma or dermatomyositis
- Psychiatric, neurologic, or addictive disorders preventing informed consent
- Pregnant or lactating females
- Known BRCA 1 or BRCA 2 mutations
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center
Cleveland, Ohio, United States, 44106-5065
Actively Recruiting
2
Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center
Cleveland, Ohio, United States, 44195
Actively Recruiting
Research Team
J
Janice Lyons, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here